Anti-CSPG4 monoclonal antibody (28) and CSPG4 siRNA/shRNA (27, 29) inhibit melanoma breast cancer growth in mouse xenografts, indicating that lowering CSPG4 function/expression limits tumor growth and/or survival. Here, CSPG4 is linked to neoplasm.